Diabetic Neuropathy: Regenerative Options When Nothing Else Has Worked

By Dr. Farhan Abdullah, DO | Medical Director, Magnolia Functional Wellness | Southlake, TX

There's a particular look patients get when they've been living with diabetic nerve pain for a few years. It isn't dramatic. It's tired. They've tried gabapentin and felt foggy. They've tried duloxetine and felt flat. They've bought the compression socks, the foot cream, the vitamin bundle from the internet. And they still wake up at three in the morning because the bedsheet touching their toes feels like sandpaper. By the time they sit down across from me, the question isn't "what is this?" anymore. It's "is there anything left?"

I'm Dr. Farhan Abdullah, and I still work as a hospitalist in Dallas alongside running Magnolia Functional Wellness in Southlake. In the hospital, I see the far end of diabetic neuropathy: the foot wound nobody felt, the infection that crept up the leg, the amputation conversation. In the clinic, I see people earlier, when there's still a lot of nerve worth protecting. Both settings have taught me the same lesson. People with stubborn neuropathy deserve a straight answer about what the newer options can and can't do, and they rarely get one.

So that's what this post is. November is Diabetes Awareness Month, and I want to walk through the regenerative and interventional options people ask me about, what the research actually shows for each, and where I think they fit. Spoiler: none of them replace the basics. A couple of them are more interesting than you might expect.

Why diabetic nerves get stuck

Diabetic peripheral neuropathy usually starts in the longest nerves first, which is why the toes and soles go before the fingers. Doctors call it a "stocking and glove" pattern. Years of high blood sugar damage the tiny blood vessels that feed those nerves, generate inflammatory byproducts, and wear down the Schwann cells that insulate nerve fibers. The result is a nerve that's underfed, inflamed, and poorly insulated, all at once.

How common is it? A Cochrane review led by Callaghan and colleagues in 2012 put it at roughly 10% of people at the time of their diabetes diagnosis and 40% to 50% after ten years. That's a staggering number of feet in North Texas alone.

Symptoms split into two camps, and they often overlap. There's the "positive" side: burning, electric jolts, pins and needles, pain from light touch. Then there's the "negative" side: numbness, poor balance, not feeling the floor clearly. Patients usually come in about the pain. I worry more about the numbness, because numbness is what lets a blister on a hot pool deck in July turn into a wound nobody notices for a week.

Here's why it's so hard to treat. Most of our standard medications work on the pain signal. They turn down the volume in the spinal cord or the brain. They don't change the environment around the damaged nerve. That's a reasonable strategy, and for plenty of people it's enough. But when it isn't enough, or when the side effects are worse than the pain, people start asking about options that try to change the biology instead of muting it.

First, the part nobody wants to hear: the foundation still matters

I'd be doing you a disservice if I skipped straight to injections. When someone tells me nothing has worked, the first thing I do is check whether the basics were ever really in place. Surprisingly often, they weren't.

Blood sugar control is the obvious one, and the evidence is more nuanced than most people realize. That same Callaghan Cochrane review pooled 17 randomized trials. In type 1 diabetes, tighter glucose control clearly reduced the risk of developing clinical neuropathy. In type 2 diabetes, the benefit was smaller and didn't quite reach formal statistical significance, though nerve conduction and vibration testing did improve. And in both groups, aggressive control raised the risk of severe low blood sugar episodes. So the goal isn't "as low as possible." It's steady, safe, and sustained.

Then there's exercise, which I think is the most underused nerve treatment we have. A small pilot study by Kluding and colleagues, published in the Journal of Diabetes Complications in 2012, put 17 people with diagnosed diabetic neuropathy through a supervised 10-week aerobic and strength program. Pain scores dropped, neuropathy symptom scores improved, and skin biopsies showed more branching of the small nerve fibers in the thigh. It had no control group, so I hold it loosely. Still, a measurable change in actual nerve fibers after ten weeks of exercise? That gets my attention.

Beyond those two, my checklist before calling anyone "refractory" includes:

• A B12 level, especially for anyone on metformin, since long-term use can lower it and B12 deficiency causes its own neuropathy
• Thyroid function, kidney function, and an honest conversation about alcohol
• A real trial of first-line medications at adequate doses, which many patients never actually got
• A foot exam and, when indicated, a vascular check, because poor circulation changes everything about what's safe

If those boxes are checked and you're still hurting, then yes, it's fair to look further.

PRP around the nerve: early but encouraging

Platelet-rich plasma is made from your own blood. We draw a tube, spin it in a centrifuge, and concentrate the platelets, which carry growth factors involved in tissue repair and blood vessel formation. Most people know PRP from knees and tendons. Using it around nerves is a newer idea, and the rationale is fairly simple: if part of the problem is a starved, inflamed nerve environment, maybe concentrated growth factors placed right next to the nerve can shift that environment.

The study I point patients to is a randomized trial by Hassanien and colleagues, published in Pain Medicine in 2020. Sixty adults with type 2 diabetes and at least six months of neuropathy were split into two groups. One got ultrasound-guided PRP injected around the nerves of the lower leg plus their usual medications. The other stayed on medications alone. Over six months of follow-up, the PRP group had significantly better pain scores, better numbness scores, and better results on a standardized clinical neuropathy scale at one, three, and six months.

That's an encouraging result. It's also one trial, from one center, with 60 people, and the comparison group didn't receive a sham injection. Placebo effects in pain studies are powerful, and a procedure with ultrasound and a needle is about as placebo-friendly as it gets. So what I tell patients is this: PRP for diabetic neuropathy is a reasonable thing to try in the right person, it uses your own tissue so the safety profile is favorable, and it isn't proven. Anyone who promises you nerve regeneration from a few PRP sessions is selling, not practicing medicine.

Who do I think is a reasonable candidate? Someone whose blood sugar is reasonably controlled, whose circulation is adequate, who has no active foot wound or infection, and who understands that we're measuring results with real numbers. At Magnolia, we track pain and numbness scores before and after, so we know whether it helped rather than guessing. You can read more about how we use it on our PRP injections page.

Exosomes and cell-based therapies: interesting science, thin human data

This is the question I get the most, usually phrased as "can stem cells fix my nerves?" I wrote about exosomes and neuropathy in more depth earlier this fall, so I'll keep this tighter.

The biology is compelling. Mesenchymal stem cells release signaling packets called exosomes that, in animal models, calm nerve inflammation, support Schwann cells, and encourage blood vessel growth. Diabetic neuropathy is one of the models where those effects have been studied. The problem is the jump from mouse to human. The human trials in diabetic neuropathy specifically are small, early, and inconsistent in how products are made and dosed.

I want to be clear about something, because it matters for your safety and your wallet. None of the regenerative options in this article, PRP, exosomes, or cell-based products, are approved treatments for diabetic neuropathy. They're used off-label or as experimental care, and they should be described to you that way. When we discuss orthobiologics at Magnolia, we talk about sourcing, realistic odds, and what we'll measure to decide whether it's working. If a clinic skips that conversation, that tells you something.

Where do exosomes fit for diabetic neuropathy right now? For most people, after the foundation is solid and after PRP has been considered, and only with eyes wide open about the evidence. I'd rather tell you that plainly than have you find out the expensive way.

The option most people haven't heard of: high-frequency spinal cord stimulation

This one isn't regenerative in the biological sense, and it isn't something we perform at Magnolia. But I'd be leaving out the strongest evidence in the whole field if I didn't mention it, and I refer patients for it when it fits.

Spinal cord stimulation uses thin leads placed near the spinal cord, connected to a small implanted battery, to change how pain signals travel. The landmark study here is the SENZA-PDN trial, published by Petersen and colleagues in JAMA Neurology in 2021. They randomized 216 people whose diabetic nerve pain hadn't responded to gabapentin-type medications plus at least one other class. At three months, 79% of the stimulation group had at least 50% pain relief without worsening of their nerve exam, compared to 5% of the group on medications alone. Average pain scores in the stimulation group fell from 7.6 to 1.7 out of 10 by six months.

Those are remarkable numbers. A few honest caveats: the trial was open-label, so participants knew which group they were in, the device manufacturer funded the study and employed some of the authors, and two people needed their devices removed because of infection. It's surgery, with surgical risks. Even so, for someone with severe, truly refractory pain, it deserves a place in the conversation, and too many patients have never been told it exists.

One more detail from that trial caught my eye as an internist. A majority of patients in the stimulation group showed improvement on their neurological exam at six months, not just less pain. Researchers are still sorting out what that means. It's a reminder that this field is moving, and that "nothing else has worked" might really mean "nothing else has been tried yet."

How I put it together for a real patient

Let me sketch what this looks like in practice, because the order matters as much as the options.

Say a 62-year-old man from Keller comes in with five years of burning feet. His A1c has hovered around 8. He tried gabapentin for two weeks, hated it, and stopped. He's on metformin and has never had a B12 level checked. He walks the dog, but that's it for exercise.

He's not refractory. Not yet. He's under-treated. We'd start by checking B12, thyroid, and kidney function, examining his feet and pulses, and working with his primary care doctor on steadier glucose control. We'd build a gradual exercise plan that protects his feet. We'd revisit medication with a slower titration or a different class. And we'd set a date, maybe three months out, to reassess with actual scores.

If at that point he's still miserable, with good circulation and no wounds, then perineural PRP becomes a reasonable next step, with clear expectations and measured outcomes. If his pain is severe and dominates his life despite all of it, I'd want him evaluated by a pain specialist for spinal cord stimulation. Exosomes sit further down that list for now, offered only with a frank talk about how early the evidence is.

That's less exciting than a single miracle injection. It's also how people actually get better.

If you've been told there's nothing left to try for your diabetic neuropathy, I'd gently push back on that. There's often a missed foundation piece, and beyond that, there are a few newer options with real, if imperfect, data behind them. At Magnolia Functional Wellness in Southlake, my job is to help you sort through them clearly, in the right order, and to protect the nerves you still have along the way. Check your feet tonight. Seriously. Then let's talk.